Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06230523 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT06230523 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 263 participants.
The verdict
NCT06230523, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.
Interventions
- DRUG Placebo
- DRUG Eloralintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2025-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06230523
The ClinicalTrials.gov registry entry for NCT06230523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06230523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06230523 about?
NCT06230523 is a clinical study titled "A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight". The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 vi...
What is the current status of trial NCT06230523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2024-02-05. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT06230523?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT06230523?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.